RAAMSDONKSVEER, 1 September 2026 – Dopharma has appointed Frido Leendertse RA as Group Chief Financial Officer (CFO). With this appointment, the veterinary pharmaceutical company strengthens its leadership team and takes an important step in supporting its international growth strategy.
The appointment comes at a pivotal moment for Dopharma. Following the launch of its Export Growth Strategy, the company is accelerating its expansion beyond Europe, with a particular focus on high-growth markets in Asia, the Middle East, North Africa and Sub-Saharan Africa. As Dopharma continues to expand its international footprint, further professionalisation of its financial organisation is essential to support sustainable growth.
Frido Leendertse has been closely involved with Dopharma over the past two years as Interim Financial Consultant. During this period, he supported the company on a broad range of financial and strategic projects and worked closely with both management and the Supervisory Board. This has provided him with a deep understanding of Dopharma’s ambitions, culture and long-term vision.
As Group CFO, Leendertse will focus on strengthening financial governance, enhancing management information and supporting the company’s increasing international activities. His responsibilities will include further professionalising financial processes and creating the financial foundation required for continued international expansion, strategic partnerships and future growth opportunities.
Frido Leendertse, Group CFO Dopharma:
“Dopharma is entering an exciting new phase of international growth. Building a strong financial organisation is essential to support this ambition. My goal is to further strengthen our financial processes and provide management with reliable insights that enable effective decision-making. By doing so, we can create a solid foundation for sustainable international expansion and future strategic opportunities.”
Wijnand de Bruijn, CEO Business Dopharma:
“International growth is a key strategic priority for Dopharma. We see significant opportunities in markets outside Europe and are investing in the capabilities needed to support that growth. Frido brings a combination of financial expertise, strategic insight and knowledge of our organisation that will help us realise our ambitions in a responsible and sustainable way.”
Dopharma recently confirmed that its international growth programme is progressing according to plan. Key milestones include the rapid development of the company’s planned Asian affiliate and an increased focus on strengthening the Dopharma brand internationally. These initiatives form part of a broader strategy aimed at accelerating growth in international markets and building a strong, long-term global presence.
With the appointment of Frido Leendertse, Dopharma further strengthens its leadership team as it continues to build the next phase of its international development.
More information: [email protected]
